New York, Feb 6, 2026, 08:55 EST — Premarket
- Pfizer shares slipped roughly 1.1% in premarket trading following Thursday’s TrumpRx rollout, which reignited concerns over U.S. drug pricing.
- Pfizer announced its TrumpRx program includes over 30 medicines, offering self-pay patients discounts of up to 85%
- The FDA has granted Priority Review for an expanded Hympavzi label, with a decision expected in the second quarter.
Pfizer Inc (PFE.N) shares slipped roughly 1.1% to $26.49 in premarket action Friday, following Thursday’s close near $26.79.
The White House rolled out TrumpRx.gov late Thursday, a discount drug portal centered on “most-favored nation” deals that swap lower U.S. prices for tariff exemptions, Reuters reported. The site mainly targets cash-paying consumers, with most purchases unlikely to count toward insurance deductibles. That raises doubts about the actual savings for insured patients, said Juliette Cubanski, deputy director for Medicare policy at KFF. Reuters
Pfizer announced its TrumpRx program provides discounts on over 30 medicines, cutting prices by up to 85% and averaging around 50% savings for uninsured patients — as well as insured patients opting to pay out of pocket. “For far too long, Americans have shouldered a disproportionate share of the global cost of innovation,” said CEO Albert Bourla. Pfizer
The company announced the FDA has granted Priority Review for expanding use of its hemophilia drug Hympavzi to patients as young as 6, including those with inhibitors—antibodies that can undermine factor-replacement therapy. The FDA’s Prescription Drug User Fee Act (PDUFA) action date is set for Q2 2026. Pfizer’s Michael Vincent highlighted “a significant medical need for younger patients with hemophilia.” Guy Young, head of the Hemostasis and Thrombosis Center at Children’s Hospital Los Angeles, stressed that bleed prevention is “particularly important to protect growing joints” in children. Business Wire
Investors face mixed signals. TrumpRx highlights policy pressure squeezing U.S. drug prices, but the Hympavzi update brings a concrete pipeline milestone with a defined regulatory timeline.
The key issue is how fast discounted, direct-to-consumer channels move from niche players to benchmarks for insurers and employers. If that shift takes hold, net prices — the amounts paid after rebates and discounts — could drop even if list prices remain unchanged.
However, the discounts might not boost demand as expected. If TrumpRx simply moves current prescriptions into cheaper options, Pfizer could end up absorbing the margin loss with little gain.
Investors will be keeping an eye on Pfizer’s stock when regular trading kicks off, looking for signs of movement. They’ll also watch if other major drugmakers expand their offerings or push deeper discounts under the TrumpRx banner. Any major shift in pricing expectations will probably surface first among the sector’s largest, most widely held companies.
Pfizer is gearing up for a key FDA ruling on the Hympavzi label expansion expected in the second quarter. Income-focused investors are also eyeing the company’s upcoming quarterly dividend payout slated for March 6.
